News

Commission funds Mutabilis project
Enlarge image

FundingFranceEU

Commission funds Mutabilis project

19.09.2012 - Mutabilis has received €4m funding from the European Union under its FP7 programme.

The project, submitted by the French specialist for infectious diseases, is called "HIVINNOV – generation of a new class of antiretrovirals targeting HIV-cellular cofactors interactions". Mutabilis, which is the coordinator of the €10.8m project, formed the consortium in July 2011 comprising eleven research institutions from across Europe. "The Commission was apparently very impressed with the major advances we have made with the compounds we are developing, as well as the quality of the consortium and the research projects proposed," said the scientific director of Mutabilis, Dr. Richard Benarous.

Mutabilis was founded in 2001 to develop new antibiotic treatments.  The French company raised €11.8m in two financing rounds in 2002 and 2004. Mutabilis runs different collaborations, amongst others with German drug developer 4SC. In 2009 FAB Pharmaceuticals SAS acquired Mutabilis lead compound Fab-001, which is a marrow- spectrum antibiotic targeting the fatty acid biosynthesis in S. aureus. Since 2010, the company has been an affiliate of Pharma Omnium International.

The European Union's seventh framework program (FP7), which has been allotted a total budget of €50.5bn for the 2007-2013 period, brings together all the EU's research initiatives under one roof and plays an important role in achieving its growth, competitiveness and employment targets. A budget of €6.05 billion has been assigned to cooperation in human health.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-03/commission-funds-mutabilis-project.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 One of the biggest pharma mergers of the year has been called off. Abbvie has dropped plans to acquire UK’s Shire following new US tax rules.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2085.7%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR146.7%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014